Which has better earnings and valuation, CYRX or IMUX?

CryoPort has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $182.94M 4.43 $78.30M $1.35 11.90 Immunic N/A N/A -$97.17M -$5.58 N/A

Is CYRX or IMUX more profitable?

CryoPort has a net margin of 41.57% compared to Immunic's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort 41.57% -7.92% -4.79% Immunic N/A -220.75% -132.04%

Does the media favor CYRX or IMUX?

In the previous week, CryoPort had 1 more articles in the media than Immunic. MarketBeat recorded 3 mentions for CryoPort and 2 mentions for Immunic. CryoPort's average media sentiment score of 1.40 beat Immunic's score of 0.93 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, OCS or IMUX?

Immunic has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 517.02 -$119.44M -$2.13 N/A Immunic N/A N/A -$97.17M -$5.58 N/A

Is OCS or IMUX more profitable?

Immunic has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Immunic N/A -220.75% -132.04%

Does the media favor OCS or IMUX?

In the previous week, Oculis had 2 more articles in the media than Immunic. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat Oculis' score of 0.78 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZVRA or IMUX more profitable?

Zevra Therapeutics has a net margin of 101.58% compared to Immunic's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Zevra Therapeutics 101.58% 51.49% 28.86% Immunic N/A -220.75% -132.04%

Does the media prefer ZVRA or IMUX?

In the previous week, Zevra Therapeutics had 2 more articles in the media than Immunic. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat Zevra Therapeutics' score of 0.89 indicating that Immunic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMUX or SPRY more profitable?

Immunic has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -153.61% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% ARS Pharmaceuticals -200.00% -153.61% -60.85%

Does the media favor IMUX or SPRY?

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Immunic. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat ARS Pharmaceuticals' score of 0.57 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACRS or IMUX?

In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 2 articles in the media. Aclaris Therapeutics' average media sentiment score of 1.89 beat Immunic's score of 0.93 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunic (IMUX) Competitors

$14.69 +0.05 (+0.34%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$14.91 +0.22 (+1.49%)

As of 07:52 AM Eastern

Compare

IMUX vs. CYRX, OCS, ZVRA, SPRY, and ACRS

Should you buy Immunic stock or one of its competitors? MarketBeat compares Immunic with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunic include CryoPort (CYRX), Oculis (OCS), Zevra Therapeutics (ZVRA), ARS Pharmaceuticals (SPRY), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Immunic compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Immunic (NASDAQ:IMUX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

CryoPort has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$182.94M	4.43	$78.30M	$1.35	11.90
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

In the previous week, CryoPort had 1 more articles in the media than Immunic. MarketBeat recorded 3 mentions for CryoPort and 2 mentions for Immunic. CryoPort's average media sentiment score of 1.40 beat Immunic's score of 0.93 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has a net margin of 41.57% compared to Immunic's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Immunic	N/A	-220.75%	-132.04%

92.9% of CryoPort shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 9.5% of CryoPort shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CryoPort has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Immunic has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

CryoPort presently has a consensus target price of $15.11, indicating a potential downside of 5.97%. Immunic has a consensus target price of $47.57, indicating a potential upside of 223.84%. Given Immunic's stronger consensus rating and higher possible upside, analysts clearly believe Immunic is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

CryoPort beats Immunic on 13 of the 16 factors compared between the two stocks.

How does Immunic compare to Oculis?

Oculis (NASDAQ:OCS) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Oculis had 2 more articles in the media than Immunic. MarketBeat recorded 4 mentions for Oculis and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat Oculis' score of 0.78 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

22.3% of Oculis shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immunic has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	517.02	-$119.44M	-$2.13	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Immunic has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Immunic	N/A	-220.75%	-132.04%

Oculis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Oculis currently has a consensus target price of $38.33, indicating a potential upside of 196.47%. Immunic has a consensus target price of $47.57, indicating a potential upside of 223.84%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Immunic beats Oculis on 10 of the 16 factors compared between the two stocks.

How does Immunic compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

In the previous week, Zevra Therapeutics had 2 more articles in the media than Immunic. MarketBeat recorded 4 mentions for Zevra Therapeutics and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat Zevra Therapeutics' score of 0.89 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.25	$83.23M	$1.99	6.56
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Immunic's net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Immunic	N/A	-220.75%	-132.04%

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 5.5% of Immunic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zevra Therapeutics currently has a consensus price target of $29.29, indicating a potential upside of 124.24%. Immunic has a consensus price target of $47.57, indicating a potential upside of 223.84%. Given Immunic's stronger consensus rating and higher possible upside, analysts plainly believe Immunic is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Zevra Therapeutics beats Immunic on 9 of the 16 factors compared between the two stocks.

How does Immunic compare to ARS Pharmaceuticals?

Immunic (NASDAQ:IMUX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

51.8% of Immunic shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Immunic has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
ARS Pharmaceuticals	$84.28M	8.97	-$171.30M	-$2.01	N/A

In the previous week, ARS Pharmaceuticals had 4 more articles in the media than Immunic. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 2 mentions for Immunic. Immunic's average media sentiment score of 0.93 beat ARS Pharmaceuticals' score of 0.57 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunic has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Immunic presently has a consensus price target of $47.57, indicating a potential upside of 223.84%. ARS Pharmaceuticals has a consensus price target of $28.20, indicating a potential upside of 270.57%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Immunic has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -153.61% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Summary

Immunic and ARS Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Immunic compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Aclaris Therapeutics has higher revenue and earnings than Immunic. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	96.85	-$64.92M	-$0.56	N/A
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

Aclaris Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Immunic has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Aclaris Therapeutics presently has a consensus target price of $11.50, indicating a potential upside of 111.79%. Immunic has a consensus target price of $47.57, indicating a potential upside of 223.84%. Given Immunic's higher probable upside, analysts plainly believe Immunic is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Aclaris Therapeutics and Aclaris Therapeutics both had 2 articles in the media. Aclaris Therapeutics' average media sentiment score of 1.89 beat Immunic's score of 0.93 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Immunic has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Immunic	N/A	-220.75%	-132.04%

Summary

Aclaris Therapeutics beats Immunic on 8 of the 14 factors compared between the two stocks.

Get Immunic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMUX vs. The Competition

Export

Metric	Immunic	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$199.42M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-2.63	20.98	26.96	24.38
Price / Sales	N/A	311.10	518.38	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	-26.71	8.54	10.90	6.33
Net Income	-$97.17M	$23.83M	$3.59B	$331.02M
7 Day Performance	-0.54%	-2.77%	-1.51%	-0.33%
1 Month Performance	4.85%	5.85%	2.76%	-1.29%
1 Year Performance	76.33%	52.15%	28.54%	21.30%

Immunic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMUX Immunic	3.4122 of 5 stars	$14.69 +0.3%	$47.57 +223.8%	+74.9%	$199.42M	N/A	N/A	70
CYRX CryoPort	3.223 of 5 stars	$15.71 -2.8%	$15.11 -3.8%	+114.3%	$791.78M	$176.18M	11.64	1,186
OCS Oculis	3.0087 of 5 stars	$13.15 -3.5%	$38.33 +191.5%	-28.8%	$790.32M	N/A	N/A	2	Positive News Analyst Downgrade
ZVRA Zevra Therapeutics	4.35 of 5 stars	$13.18 -1.3%	$29.29 +122.2%	+2.1%	$779.14M	$122.29M	6.62	20	Analyst Upgrade
SPRY ARS Pharmaceuticals	3.2531 of 5 stars	$7.74 -2.5%	$28.20 +264.3%	-57.5%	$768.61M	$98.99M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMUX) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunic (IMUX) Competitors

IMUX vs. CYRX, OCS, ZVRA, SPRY, and ACRS

How does Immunic compare to CryoPort?

Summary

How does Immunic compare to Oculis?

Summary

How does Immunic compare to Zevra Therapeutics?

Summary

How does Immunic compare to ARS Pharmaceuticals?

Summary

How does Immunic compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunic (IMUX) Competitors

IMUX vs. CYRX, OCS, ZVRA, SPRY, and ACRS

How does Immunic compare to CryoPort?

Which has better earnings and valuation, CYRX or IMUX?

Does the media favor CYRX or IMUX?

Is CYRX or IMUX more profitable?

Do institutionals and insiders believe in CYRX or IMUX?

Which has more risk and volatility, CYRX or IMUX?

Do analysts rate CYRX or IMUX?

Summary

How does Immunic compare to Oculis?

Does the media favor OCS or IMUX?

Do insiders and institutionals believe in OCS or IMUX?

Which has higher valuation and earnings, OCS or IMUX?

Is OCS or IMUX more profitable?

Which has more volatility and risk, OCS or IMUX?

Do analysts rate OCS or IMUX?

Summary

How does Immunic compare to Zevra Therapeutics?

Does the media prefer ZVRA or IMUX?

Which has more volatility and risk, ZVRA or IMUX?

Which has higher earnings and valuation, ZVRA or IMUX?

Is ZVRA or IMUX more profitable?

Do insiders & institutionals believe in ZVRA or IMUX?

Do analysts prefer ZVRA or IMUX?

Summary

How does Immunic compare to ARS Pharmaceuticals?

Do institutionals & insiders believe in IMUX or SPRY?

Which has stronger earnings & valuation, IMUX or SPRY?

Does the media favor IMUX or SPRY?

Which has more volatility & risk, IMUX or SPRY?

Do analysts prefer IMUX or SPRY?

Is IMUX or SPRY more profitable?

Summary

How does Immunic compare to Aclaris Therapeutics?

Which has better valuation and earnings, ACRS or IMUX?

Which has more volatility & risk, ACRS or IMUX?

Do analysts recommend ACRS or IMUX?

Does the media prefer ACRS or IMUX?

Do institutionals and insiders believe in ACRS or IMUX?

Is ACRS or IMUX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX vs. The Competition

Immunic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools